Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$24.51
0.281.16%
À la fermeture: -
$24.54
0.030.12%
Après les heures de négociation: Oct 17, 7:58 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Pfizer Inc a un objectif de cours consensus de $33.27, basé sur les évaluations des 24 analystes. Le plus élevé est de $50 attribué par HSBC le juillet 14, 2023, et le plus bas est de $24 attribué par Cantor Fitzgerald le avril 22, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Morgan Stanley, B of A Securities et Citigroup le octobre 10, 2025, octobre 3, 2025 et août 6, 2025. Avec un objectif de cours moyen de $29.33 entre Morgan Stanley, B of A Securities et Citigroup, il y a une variation implicite de 19.53% upside pour Pfizer Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Morgan Stanley
B of A Securities
Citigroup
UBS
Cantor Fitzgerald
1calculé à partir des notes des analystes
Notes d'analystes pour Pfizer
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/10/2025 | 30.4% | Morgan Stanley | $33 → $32 | Maintains | Equal-Weight | |||
10/03/2025 | 22.25% | B of A Securities | $28 → $30 | Maintains | Neutral | |||
08/06/2025 | 5.95% | Citigroup | $25 → $26 | Maintains | Neutral | |||
08/06/2025 | 34.47% | Morgan Stanley | $32 → $33 | Maintains | Equal-Weight | |||
08/06/2025 | 14.1% | B of A Securities | $27 → $28 | Maintains | Neutral | |||
04/30/2025 | 1.87% | UBS | $24 → $25 | Maintains | Neutral | |||
04/22/2025 | -2.2% | Cantor Fitzgerald | → $24 | Initiates | → Neutral | |||
04/08/2025 | -2.2% | UBS | $28 → $24 | Maintains | Neutral | |||
04/08/2025 | 1.87% | Goldman Sachs | $32 → $25 | Downgrade | Buy → Neutral | |||
03/18/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
03/12/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
02/10/2025 | 34.47% | Guggenheim | $33 → $33 | Reiterates | Buy → Buy | |||
02/05/2025 | 14.1% | UBS | $29 → $28 | Maintains | Neutral | |||
01/28/2025 | 18.17% | Citigroup | $30 → $29 | Maintains | Neutral | |||
01/08/2025 | 18.17% | UBS | $31 → $29 | Maintains | Neutral | |||
12/18/2024 | 30.4% | Truist Securities | $36 → $32 | Maintains | Buy | |||
12/11/2024 | 34.47% | Guggenheim | $35 → $33 | Maintains | Buy | |||
12/10/2024 | 18.17% | B of A Securities | → $29 | Reinstates | → Neutral | |||
11/15/2024 | 1.87% | Wolfe Research | → $25 | Initiates | → Underperform | |||
10/30/2024 | 26.32% | Morgan Stanley | $30 → $31 | Maintains | Equal-Weight | |||
10/25/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
10/23/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
10/17/2024 | 30.4% | Bernstein | → $32 | Initiates | → Market Perform | |||
10/11/2024 | 22.25% | Morgan Stanley | $31 → $30 | Maintains | Equal-Weight | |||
10/03/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
09/16/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
09/09/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
08/19/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
08/08/2024 | 38.55% | Daiwa Capital | $28 → $34 | Upgrade | Neutral → Outperform | |||
07/31/2024 | 26.32% | Morgan Stanley | $29 → $31 | Maintains | Equal-Weight | |||
07/31/2024 | 30.4% | Barclays | $30 → $32 | Maintains | Equal-Weight | |||
07/31/2024 | 22.25% | Wells Fargo | $28 → $30 | Maintains | Equal-Weight | |||
07/31/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
07/31/2024 | 26.32% | UBS | $30 → $31 | Maintains | Neutral | |||
07/12/2024 | 22.25% | UBS | $28 → $30 | Maintains | Neutral | |||
07/10/2024 | 22.25% | Barclays | $28 → $30 | Maintains | Equal-Weight | |||
07/10/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
07/01/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
06/26/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
06/20/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
06/17/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
05/02/2024 | 18.17% | Morgan Stanley | $28 → $29 | Maintains | Equal-Weight | |||
05/02/2024 | 46.7% | BMO Capital | $33 → $36 | Reiterates | Outperform → Outperform | |||
04/18/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
04/15/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
04/05/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
04/01/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
03/31/2024 | 18.17% | Morgan Stanley | $28 → $29 | Maintains | Equal-Weight | |||
03/22/2024 | — | Argus Research | — | Downgrade | Buy → Hold | |||
03/04/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
03/01/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
02/23/2024 | 46.7% | Guggenheim | → $36 | Initiates | → Buy | |||
01/31/2024 | 14.1% | UBS | $29 → $28 | Maintains | Neutral | |||
01/31/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
01/17/2024 | 18.17% | UBS | $27 → $29 | Maintains | Neutral | |||
01/09/2024 | 83.37% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
01/04/2024 | 30.4% | TD Cowen | → $32 | Downgrade | Outperform → Market Perform | |||
12/14/2023 | 14.1% | Wells Fargo | $35 → $28 | Maintains | Equal-Weight | |||
12/14/2023 | 83.37% | Cantor Fitzgerald | $75 → $45 | Maintains | Overweight | |||
12/14/2023 | 46.7% | Truist Securities | $42 → $36 | Maintains | Buy | |||
12/14/2023 | 10.02% | UBS | $34 → $27 | Maintains | Neutral | |||
12/14/2023 | 14.1% | Barclays | $34 → $28 | Maintains | Equal-Weight | |||
12/04/2023 | 71.15% | Truist Securities | → $42 | Reiterates | Buy → Buy | |||
11/20/2023 | 205.62% | Cantor Fitzgerald | → $75 | Reiterates | Overweight → Overweight | |||
11/01/2023 | 38.55% | Barclays | $35 → $34 | Maintains | Equal-Weight | |||
11/01/2023 | 50.77% | Morgan Stanley | $39 → $37 | Maintains | Equal-Weight | |||
10/20/2023 | 38.55% | UBS | $36 → $34 | Assumes | Neutral → Neutral | |||
10/17/2023 | 71.15% | Truist Securities | $62 → $42 | Maintains | Buy | |||
10/17/2023 | 58.92% | Morgan Stanley | $40 → $39 | Maintains | Equal-Weight | |||
10/17/2023 | 42.62% | Wells Fargo | $39 → $35 | Maintains | Equal-Weight | |||
10/16/2023 | 34.47% | BMO Capital | $44 → $33 | Maintains | Outperform | |||
10/16/2023 | 42.62% | Citigroup | $42 → $35 | Maintains | Neutral | |||
10/16/2023 | 38.55% | JP Morgan | $36 → $34 | Maintains | Neutral | |||
10/16/2023 | 42.62% | Wells Fargo | $39 → $35 | Maintains | Equal-Weight | |||
10/16/2023 | 58.92% | Jefferies | $38 → $39 | Upgrade | Hold → Buy | |||
10/06/2023 | 46.7% | JP Morgan | $39 → $36 | Maintains | Neutral | |||
10/02/2023 | 205.62% | Cantor Fitzgerald | → $75 | Reiterates | Overweight → Overweight | |||
09/18/2023 | 205.62% | Cantor Fitzgerald | → $75 | Reiterates | Overweight → Overweight | |||
09/13/2023 | 152.65% | Truist Securities | → $62 | Reiterates | Buy → Buy | |||
09/05/2023 | 205.62% | Cantor Fitzgerald | → $75 | Reiterates | Overweight → Overweight | |||
08/30/2023 | 205.62% | Cantor Fitzgerald | → $75 | Reiterates | Overweight → Overweight | |||
08/22/2023 | 205.62% | Cantor Fitzgerald | → $75 | Reiterates | Overweight → Overweight | |||
08/02/2023 | 152.65% | Truist Securities | $64 → $62 | Maintains | Buy | |||
08/02/2023 | 63% | Morgan Stanley | $42 → $40 | Maintains | Equal-Weight | |||
08/02/2023 | 79.3% | BMO Capital | $45 → $44 | Maintains | Outperform | |||
07/21/2023 | 71.15% | Morgan Stanley | $43 → $42 | Maintains | Equal-Weight | |||
07/14/2023 | 103.75% | HSBC | → $50 | Initiates | → Buy | |||
07/11/2023 | 75.22% | Morgan Stanley | $43 → $43 | Reiterates | Equal-Weight → Equal-Weight | |||
07/11/2023 | 54.85% | Barclays | $40 → $38 | Maintains | Equal-Weight | |||
06/29/2023 | 63% | Credit Suisse | $47 → $40 | Downgrade | Outperform → Neutral | |||
06/23/2023 | 205.62% | Cantor Fitzgerald | $75 → $75 | Reiterates | Overweight → Overweight | |||
06/22/2023 | 205.62% | Cantor Fitzgerald | → $75 | Reiterates | Overweight → Overweight | |||
05/17/2023 | 205.62% | Cantor Fitzgerald | → $75 | Reiterates | Overweight → Overweight | |||
05/11/2023 | 54.85% | Daiwa Capital | $51 → $38 | Downgrade | Outperform → Neutral | |||
05/03/2023 | 91.52% | Credit Suisse | $50 → $47 | Maintains | Outperform | |||
05/03/2023 | 63% | Barclays | $43 → $40 | Maintains | Equal-Weight | |||
04/21/2023 | 83.37% | B of A Securities | $50 → $45 | Maintains | Neutral | |||
04/12/2023 | 75.22% | Barclays | $44 → $43 | Maintains | Equal-Weight | |||
04/10/2023 | 79.3% | Morgan Stanley | $45 → $44 | Maintains | Equal-Weight | |||
03/17/2023 | 79.3% | Wells Fargo | $50 → $44 | Maintains | Equal-Weight |
FAQ
Quel est le cours indicatif de l'action Pfizer (PFE) ?
Le dernier objectif de prix pour Pfizer (NYSE:PFE) a été rapporté par Morgan Stanley le octobre 10, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $32.00 s'attendant à ce que PFE se rise dans les 12 prochains mois (un possible changement de 30.40% upside). 22 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Pfizer (PFE) ?
La dernière note d'analyste pour Pfizer (NYSE:PFE) a été fournie par Morgan Stanley, et Pfizer maintenu leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour Pfizer (PFE) ?
La dernière amélioration pour Pfizer Inc a eu lieu le août 8, 2024 lorsque Daiwa Capital a augmenté leur objectif de prix à $34. Daiwa Capital avait précédemment a neutral pour Pfizer Inc.
Quand a eu lieu la dernière dégradation pour Pfizer (PFE) ?
La dernière réduction pour Pfizer Inc a eu lieu le avril 8, 2025 lorsque Goldman Sachs a changé leur objectif de prix de $32 à $25 pour Pfizer Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Pfizer (PFE) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Pfizer, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Pfizer a été déposée le octobre 10, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 10, 2026.
La note d'analyste pour Pfizer (PFE) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Pfizer (PFE) était un maintenu avec un objectif de prix de $33.00 à $32.00. Le prix actuel de Pfizer (PFE) est de $24.54, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.